Alamandine abrogates neutrophil degranulation in atherosclerotic mice.
Analina R Da SilvaSébastien LengletFederico CarboneFabienne BurgerAline RothLuca LiberaleAldo BonaventuraFranco DallegriNikolaos StergiopulosRobson A S SantosFrançois MachRodrigo A Fraga-SilvaFabrizio MontecuccoPublished in: European journal of clinical investigation (2017)
These results suggest that treatment with the MrgD agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation.